19 completed, 6 terminated, 5 recruiting, 2 active not recruiting. 37 Phase 1, 13 Phase 2.
Follow exemestane: new trials by email Literature Review of exemestane trials Research Report on exemestane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study Exemestane 25 MG, Placebo, Exemestane 50 MG - Poly Cystic Ovary Syndrome | Phase 1 | Recruiting | University of North Carolina, Chapel Hill | 40 | 2026-10-01 | 2026-09-23 |
| BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder Aromatase Inhibitors, Bupropion, GnRH agonist - Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Illinois at Chicago | 100 | 2026-09-01 | 2026-08-24 |
| Sapu003 in Advanced mTOR-sensitive Solid Tumors Sapu003, Exemestane 25 MG - Breast Cancer Metastatic, Renal Cell Carcinoma (RCC) | Phase 1 | Recruiting | SAPU NANO (US) LLC | 27 | 2025-12-15 | 2026-01-27 |
| A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors Sacituzumab Govitecan + Fulvestrant, Sacituzumab Govitecan + Anastrozole / Exemestane - Stage IV (Metastatic) Breast Cancer | Phase 1 | Not yet recruiting | Hunan Cancer Hospital | 12 | 2025-10-01 | 2025-09-16 |
| Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor - Ductal Carcinoma in Situ | Phase 1 | Recruiting | Finn, Olivera, PhD | 50 | 2024-02-07 | 2026-10-16 |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors STX-478, Fulvestrant, Ribociclib - Breast Cancer, Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 880 | 2023-04-17 | 2026-07-07 |
| Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer EP0062, Elacestrant, Everolimus - Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | Ellipses Pharma | 95 | 2023-01-11 | 2026-06-22 |
| A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors LOXO-783, Fulvestrant, Imlunestrant - Breast Cancer | Phase 1 | Active not recruiting | Eli Lilly and Company | 260 | 2022-05-11 | 2026-10-14 |
| A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer E7090, Fulvestrant, Exemestane - Breast Neoplasms | Phase 1 | Completed | Eisai Co., Ltd. | 51 | 2020-10-09 | 2026-07-17 |
| T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer Anastrozole, Exemestane, Fulvestrant - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 | Completed | University of California, San Francisco | 20 | 2020-02-05 | 2025-05-21 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat - Breast Neoplasms | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 144 | 2017-12-22 | 2025-11-10 |
| Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer Pembrolizumab/ Exemestane/ Leuprolide - Premenopausal Breast Cancer | Phase 1 / Phase 2 | Terminated | National Taiwan University Hospital | 16 | 2017-09-15 | 2023-02-22 |
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer GS-5829, Exemestane, Fulvestrant - Advanced Estrogen Receptor Positive HER2- Breast Cancer | Phase 1 / Phase 2 | Terminated | Gilead Sciences | 14 | 2017-01-10 | 2019-08-07 |
| Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer Entinostat, Exemestane - Breast Cancer | Phase 1 | Completed | Taizhou EOC Pharma Co., Ltd. | 19 | 2016-08-29 | 2019-05-07 |
| Palbociclib With Everolimus + Exemestane In BC Palbociclib, Everolimus, Exemestane - Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 41 | 2016-08-24 | 2022-08-29 |
| Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer entinostat, exemestane - Breast Cancer, Estrogen Receptor Positive Breast Cancer | Phase 1 | Completed | Syndax Pharmaceuticals | 61 | 2016-06-29 | 2021-12-15 |
| Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. Ribociclib, Everolimus, Exemestane - Breast Cancer | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 104 | 2016-06-14 | 2021-05-05 |
| Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer KHK2375, Exemestane - Breast Cancer | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 15 | 2015-11-01 | 2022-06-21 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer Alobresib, Exemestane, Fulvestrant - Solid Tumors and Lymphomas | Phase 1 | Completed | Gilead Sciences | 33 | 2015-03-16 | 2020-12-29 |
| BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer Everolimus, Exemestane, BI 836845 - Neoplasms | Phase 1 | Completed | Boehringer Ingelheim | 164 | 2014-05-15 | 2025-07-15 |
Showing 20 of 37. Sign in to see all of them.
Breast Neoplasms (26) · Neoplasms (5) · Breast Diseases (3) · Neoplasm Metastasis (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Neoplasms by Site (2) · Acrocephalosyndactylia (1) · Breast Neoplasms, Male (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1)
Eli Lilly and Company (3) · Novartis Pharmaceuticals (3) · Boehringer Ingelheim (2) · Gilead Sciences (2) · Pfizer (2) · Syndax Pharmaceuticals (2) · Actavis Inc. (1) · AstraZeneca (1) · Baylor Breast Care Center (1) · Dana-Farber Cancer Institute (1) · Eisai Co., Ltd. (1) · Ellipses Pharma (1) · Finn, Olivera, PhD (1) · Georgetown University (1) · Hoffmann-La Roche (1)
United States (25) · Spain (7) · Belgium (6) · France (6) · United Kingdom (5) · Germany (4) · Italy (4) · Japan (4) · China (3) · Netherlands (3) · South Korea (3) · Australia (2) · Canada (2) · Hong Kong (2) · Hungary (2)
Amy J Chien, MD (1) · Bruce Pier, MD (1) · Claudine Isaacs, MD (1) · Donal Landers (1) · Edward Garon (1) · Emilia Diego, MD (1) · Francisco J. Esteva, MD, PhD (1) · Howard A Burris, M.D. (1) · Julie Means-Powell, MD (1)
PMID 24919854, PMID 31322702, PMID 32864625, PMID 33451345, PMID 34196874, PMID 34819039, PMID 35223458, PMID 39384801, PMID 39730000, PMID 40974664, PMID 41271741
2016 (2), 2017 (1), 2023 (1), N01CM00100 (1), P30CA076292 (1)